ProCE Banner Activity

CASSIOPET: CASSIOPEIA Companion Study Evaluating Prognostic Value of PET/CT in Newly Diagnosed, Transplant-Eligible Myeloma

Slideset Download
Conference Coverage
PET-negative findings at baseline portend a favorable prognosis for patients with newly diagnosed MM, as does PET and MRD double negativity postconsolidation after D-VTd and transplantation.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company